A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 08 Oct 2019 Status changed from active, no longer recruiting to completed.
- 20 May 2019 Planned End Date changed from 1 Nov 2019 to 1 Oct 2019.
- 05 Jun 2018 Safety results presented at the 54th Annual Meeting of the American Society of Clinical Oncology